{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T18:47:02Z","timestamp":1771267622262,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12325-021-01807-6","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T11:03:02Z","timestamp":1625828582000},"page":"4581-4591","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase\u00a0II Trial"],"prefix":"10.1007","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct02721732","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-215X","authenticated-orcid":false,"given":"Renata","family":"Ferrarotto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luana G.","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Qing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Kaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettzy","family":"Stephen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipti","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shubham","family":"Pant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Janku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Blumenschein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie S.","family":"Glisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi Rodon","family":"Ahnert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Jack","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"issue":"10","key":"1807_CR1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","volume":"151","author":"HW Rogers","year":"2015","unstructured":"Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081\u20136.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"1807_CR2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","volume":"68","author":"PS Karia","year":"2013","unstructured":"Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957\u201366.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1807_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1200\/JCO.2005.02.155","volume":"23","author":"GL Clayman","year":"2005","unstructured":"Clayman GL, Lee JJ, Holsinger CF, et al. Mortality risk from squamous cell skin cancer. J Clin Oncol. 2005;23(4):759\u201365.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1807_CR4","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/COC.0000000000000088","volume":"39","author":"A Jarkowski 3rd","year":"2016","unstructured":"Jarkowski A 3rd, Hare R, Loud P, et al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell park experience and a review of the literature. Am J Clin Oncol. 2016;39(6):545\u20138.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1807_CR5","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1200\/JCO.2002.20.2.364","volume":"20","author":"DM Shin","year":"2002","unstructured":"Shin DM, Glisson BS, Khuri FR, et al. Phase\u00a0II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002;20(2):364\u201370.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1807_CR6","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1002\/1097-0142(19901015)66:8<1692::AID-CNCR2820660807>3.0.CO;2-Y","volume":"66","author":"H Sadek","year":"1990","unstructured":"Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66(8):1692\u20136.","journal-title":"Cancer"},{"issue":"6","key":"1807_CR7","doi-asserted-by":"publisher","first-page":"1110 e2","DOI":"10.1016\/j.jaad.2017.07.048","volume":"77","author":"WN William Jr","year":"2017","unstructured":"William WN Jr, Feng L, Ferrarotto R, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single-arm phase\u00a0II clinical trial. J Am Acad Dermatol. 2017;77(6):1110 e2-1113 e2.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1807_CR8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/cncr.31346","volume":"124","author":"KA Gold","year":"2018","unstructured":"Gold KA, Kies MS, William WN Jr, Johnson FM, Lee JJ, Glisson BS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase 2 clinical trial. Cancer. 2018;124(10):2169\u201373.","journal-title":"Cancer"},{"issue":"10","key":"1807_CR9","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/annonc\/mdu368","volume":"25","author":"MC Foote","year":"2014","unstructured":"Foote MC, McGrath M, Guminski A, et al. Phase\u00a0II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25(10):2047\u201352.","journal-title":"Ann Oncol"},{"issue":"25","key":"1807_CR10","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","volume":"29","author":"E Maubec","year":"2011","unstructured":"Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase\u00a0II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419\u201326.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1807_CR11","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34.","journal-title":"Genome Med"},{"issue":"24","key":"1807_CR12","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-14-1768","volume":"20","author":"CR Pickering","year":"2014","unstructured":"Pickering CR, Zhou JH, Lee JJ, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20(24):6582\u201392.","journal-title":"Clin Cancer Res"},{"issue":"17","key":"1807_CR13","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMra022137","volume":"348","author":"S Euvrard","year":"2003","unstructured":"Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681\u201391.","journal-title":"N Engl J Med"},{"issue":"25","key":"1807_CR14","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500\u20131.","journal-title":"N Engl J Med"},{"key":"1807_CR15","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.126908","author":"M Yarchoan","year":"2019","unstructured":"Yarchoan M, Albacker LA, Hopkins AC, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019. https:\/\/doi.org\/10.1172\/jci.insight.126908.","journal-title":"JCI Insight"},{"issue":"4","key":"1807_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341\u201351.","journal-title":"N Engl J Med"},{"issue":"25","key":"1807_CR17","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.1200\/JCO.19.03054","volume":"38","author":"JJ Grob","year":"2020","unstructured":"Grob JJ, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase\u00a0II trial (KEYNOTE-629). J Clin Oncol. 2020;38(25):2916\u201325.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1807_CR18","doi-asserted-by":"publisher","first-page":"e000347corr1","DOI":"10.1136\/jitc-2019-000347corr1","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Meric-Bernstam F, Stephen B, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020;8(1):e000347corr1.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"1807_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"1807_CR20","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"7","key":"1807_CR21","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.ejrad.2015.03.017","volume":"84","author":"M Nishino","year":"2015","unstructured":"Nishino M, Tirumani SH, Ramaiya NH, Hodi FS. Cancer immunotherapy and immune-related response assessment: the role of radiologists in the new arena of cancer treatment. Eur J Radiol. 2015;84(7):1259\u201368.","journal-title":"Eur J Radiol"},{"key":"1807_CR22","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events v4.03 (CTCAE). 2010."},{"key":"1807_CR23","volume-title":"Classification and regression trees (Wadsworth statistics\/probability)","author":"L Breiman","year":"1984","unstructured":"Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees (Wadsworth statistics\/probability). Boca Raton: Chapman and Hall\/CRC; 1984."},{"issue":"15_suppl","key":"1807_CR24","doi-asserted-by":"publisher","first-page":"10018","DOI":"10.1200\/JCO.2020.38.15_suppl.10018","volume":"38","author":"D Rischin","year":"2020","unstructured":"Rischin D, Khushalani NI, Schmults CD, et al. Phase\u00a0II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): longer follow-up. J Clin Oncol. 2020;38(15_suppl):10018\u201310018.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"1807_CR25","doi-asserted-by":"publisher","first-page":"9534","DOI":"10.1200\/JCO.2018.36.15_suppl.9534","volume":"36","author":"E Maubec","year":"2018","unstructured":"Maubec E, Boubaya M, Petrow P, et al. Pembrolizumab as first line therapy in patients with unresectable squamous cell carcinoma of the skin: interim results of the phase 2 CARSKIN trial. J Clin Oncol. 2018;36(15_suppl):9534\u20139534.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1807_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","volume":"7","author":"N Abdel-Wahab","year":"2019","unstructured":"Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J Immunother Cancer. 2019;7(1):106.","journal-title":"J Immunother Cancer"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-021-01807-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-021-01807-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T16:41:38Z","timestamp":1628613698000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-021-01807-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["1807"],"URL":"https:\/\/doi.org\/10.1007\/s12325-021-01807-6","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}